Latanoprost Actavis (Latanoprost)

Latanoprost binds to prostaglandin F (FP) receptors in the eye’s ciliary body, stimulating the uveoscleral outflow pathway. This increased drainage of aqueous humor reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension.

The dosing regimen for Latanoprost Actavis is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

The safety of latanoprost in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and use should be considered only if the potential benefit justifies any potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally provides the greatest IOP‑lowering effect with once‑daily dosing. Compared with beta‑blockers or carbonic anhydrase inhibitors, latanoprost often achieves larger pressure reductions and has a different side‑effect profile, such as increased eyelash growth and iris pigmentation.

Latanoprost Actavis should be stored at room temperature, below 25 °C. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the manufacturer.

The medication is applied topically as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks, though rare, include severe ocular inflammation such as uveitis, allergic reactions that may cause swelling or rash around the eye, and macular edema which can affect central vision. Any sudden vision changes or intense eye pain should prompt immediate medical evaluation.

Patients with known hypersensitivity to latanoprost or any component of the formulation should avoid its use. It is also contraindicated in individuals with active ocular infections or severe inflammation until those conditions are resolved.